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Abstract
Objective: To examine the incremental predictive value of genetic risk scores of coronary
heart disease (CHD) in the 10-year risk prediction of incident CHD.
Methods: In 5899 subjects, we used 152 single nucleotide polymorphisms (SNPs) associ-
ated with coronary artery disease by the CARDIoGRAMplusC4D consortium to construct
three weighted genetic risk scores: (i) GRSgws based on 49 genome-wide significant
SNPs; (ii) GRSfdr based on 103 suggestively associated SNPs; and (iii) GRSall based on all
152 SNPs. We examined the changes in discrimination and reclassification of incident
CHD when adding the genetic risk scores to models including traditional risk factors. We
repeated the analysis for prevalent CHD.
Results: The genetic risk scores were associated with incident CHD despite adjustment for
traditional risk factors and family history: participants had a 13% higher rate of CHD per
standard deviation increase in GRSall. GRSall improved the C-statistic by 0.006 [95% confi-
dence interval (CI): 0.000, 0.013] beyond age and sex, 0.003 (95% CI: 0.001, 0.008) beyond
traditional risk factors and 0.003 (95% CI: 0.001, 0.007) beyond traditional risk factors and
family history. The genetic risk scores did not improve reclassification. GRSall strongly im-
proved both discrimination and reclassification of prevalent CHD, even beyond traditional
risk factors and family history, with a C-statistic improvement of 0.009 (0.003, 0.015).
Conclusions: Although the genetic risk scores based on 152 SNPs were associated with
incident CHD, they did not improve risk prediction. This discrepancy may be the result of
SNP discovery for prevalent rather than incident CHD, since the SNPs do improve predic-
tion for prevalent disease.
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Introduction
Primary and secondary prevention programmes are widely
performed using risk prediction models based on trad-
itional risk factors to identify individuals at high risk for
coronary heart disease (CHD). Optimizing these risk pre-
diction models could therefore directly translate into im-
proved prevention and management of CHD-related
morbidity and mortality. As CHD has a strong heritable
component,1,2 adding genetic markers to prediction mod-
els could improve risk prediction. This assumption has
been tested in studies using genetic risk scores based on sin-
gle nucleotide polymorphisms (SNPs).3–13 Overall, the
studies show that prediction is not meaningfully improved
by currently validated CHD SNPs.3–13 Nevertheless, the
set of CHD SNPs is growing through the efforts of interna-
tional consortia, and a recent genome-wide association
study (GWAS) by the CARDIoGRAMplusC4D consortium
raised the number of independent CHD SNPs from 31to
153.14 Collectively these SNPs explain around 10% of the
genetic variance,14 which suggests that we are now in a
better position to implement SNPs in risk prediction
of CHD.
These SNPs, however, were identified using case-
control and cross-sectional designs. In these study designs,
SNPs associated with a favourable prognosis after CHD
events may be overrepresented in cases. As a consequence,
the association of these SNPs may not fully translate to in-
cident CHD, leading to markers that are spuriously associ-
ated with CHD.
We hypothesized that adding genetic risk scores based
on CHD SNPs would improve 10-year CHD risk predic-
tion when added to traditional risk factors.To evaluate our
hypothesis, we constructed three genetic risk scores based
on CHD SNPs found by the CARDIoGRAMplusC4D con-
sortium. We then examined whether risk prediction im-
proved when we added the genetic risk scores to three
models including: (i) age and sex; (ii) age, sex and trad-
itional risk factors; and (iii) age, sex, traditional risk fac-
tors and family history. To examine differences between




This study was conducted within the Rotterdam Study, an
ongoing prospective population-based cohort study of in-
habitants of Ommoord, a district of Rotterdam in The
Netherlands. The Rotterdam Study has been described in
detail elsewhere.15,16 In the year 1990, inhabitants of
Ommoord who were 55 years old or over were invited to
participate. Baseline examination lasted from 1990 to
1993 and included 7983 participants, of whom 7758 gave
their informed consent for follow-up data collection.
Follow-up examinations were carried out every 3 to 5
years. The study was approved by the Medical Ethics
Committee of Erasmus University, Rotterdam, The
Netherlands, and all included participants gave their writ-
ten informed consent.
Genotyping and imputation
Genotyping was successfully conducted in 5899 partici-
pants who agreed to be followed-up, using the Illumina
550 K. Imputation was done with reference to HapMap re-
lease 22 CEU using the maximum likelihood method im-
plemented in MACH.17–19 The imputation quality of the
SNPs is presented in Supplementary Table 1 (available as
Supplementary data at IJE online).
Genetic risk scores
To construct genetic risk scores, we used 153 uncorrelated
SNPs associated with CHD by the CARDIoGRAMplusC4D
consortium, of which 49 attained genome-wide significance
and the remaining 104 had a false discovery rate (FDR) of
less than 10% in an FDR analysis.14 Out of the 153 SNPs,
152 were either genotyped or imputed in the Rotterdam
Key Messages
• Genetic risk scores do not improve risk prediction of incident coronary heart disease (CHD) over traditional risk
factors.
• The same genetic risk scores do improve the identification of individuals with prevalent CHD.
• Adding suggestively associated genetic variants to the genetic risk score strengthened the association with incident
CHD.
• The genetic risk scores provided largely independent information on top of family history.
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Study. We calculated weighted dosages by multiplying the
risk allele (the allele previously reported to increase the risk
of CHD) dosage of each SNP with its previously reported
effect size (lnOR)14. GRSgws was constructed using the 49
genome-wide significant SNPs, GRSfdr using the 103 add-
itional SNPs that were found in the FDR analysis, and
GRSall using all 152 SNPs. Genetic risk scores were com-
puted using the PredictABEL package in R version 2.15.1
(R Foundation for Statistical Computing, Vienna,
Austria).20
Coronary heart disease
CHD events included myocardial infarctions, all CHD
mortality and revascularization. Cardiovascular outcome
definitions as well as data collection methods are presented
in detail elsewhere.21 In brief, participants with general
practitioners in the district of Ommoord were continuously
monitored for fatal and nonfatal cardiovascular events
through automated linkage with files from general practi-
tioners and hospitals. Participants with general practi-
tioners outside Ommoord were monitored through annual
checks of their medical records. All reported events were
independently reviewed and coded by two research phys-
icians. Codes on which the research physicians disagreed
were discussed to reach consensus, and a medical expert in
cardiovascular disease subsequently reviewed all events.
Traditional risk factors and family history
Serum total and high-density lipoprotein (HDL) choles-
terol concentrations were determined at baseline within 2
weeks after sampling by an automated enzymatic proced-
ure in non-fasting blood samples (Kone Specific Analyzer,
Kone Instruments). Blood pressure was measured while
seated, using a random-zero sphygmomanometer at the
right brachial artery. The average of two consecutive meas-
urements was used. Diabetes was defined as fasting plasma
glucose levels 7 mmol/l or non-fasting plasma glucose
11.1 mmol/l or use of medications indicated for the treat-
ment of diabetes. Current smoking status (yes/no), family
history of myocardial infarction in first-degree relatives
(yes/no), lipid-lowering medication use (yes/no) and anti-
hypertensive medication use (yes/no) were assessed during
a structured interview at baseline by trained research
assistants.
Statistical analyses
Statistical analyses were done using SPSS version 20 (IBM,
Armonk, NY) and R version 2.15.1. Missing values for all
covariates were imputed using expectation maximization
in SPSS. Participants with prevalent CHD at baseline were
excluded, and hazard rates were computed using Cox pro-
portional hazard models. Three adjustment models were
used. Model 1 was adjusted only for age and sex. Model 2
was further adjusted for total and HDL cholesterol, sys-
tolic blood pressure, prevalent type 2 diabetes, antihyper-
tensive medication, lipid-lowering medication and current
smoking. Model 3 was additionally adjusted for family
history of myocardial infarction. In addition to standard
P-values, we computed Bonferroni corrected P-values for
the associations of the genetic risk scores with incident
CHD, using the p.adjust function in R. We applied a cor-
rection for nine statistical tests (the three genetic risk scores
were each tested in three models). All models met the as-
sumption of proportional hazards, which was tested for
each model using the ‘cox.zph’ function in R. Absolute 10-
year risk was estimated as explained by Wilson et al.22
These predicted risks were used to classify participants into
low (<5%), intermediate-low (5–10%), intermediate-high
(10–20%) and high (>20%) risk categories. Changes in C-
statistic were used to assess improvements in discrimin-
ation, and the categorical net reclassification improvement
(NRI) was used to assess improvements in reclassifica-
tion.23 NRIs were calculated using the prospective form
applicable to survival data as introduced by Pencina
et al.24 We used 10 000 bootstrap resamples to generate
95% confidence intervals for changes in C-statistic and
prospective NRI. We performed several additional ana-
lyses. First, improvements in prediction were also calcu-
lated in the subgroup of 2082 participants who were under
65 years old at baseline. Second, we examined the associ-
ation of the genetic risk scores with myocardial infarction
and estimated the corresponding improvements in predic-
tion. Furthermore, we used Cox proportional hazard mod-
els to examine the association between family history and
incident CHD, using different adjustments: age- and sex-
adjusted, further adjusted for traditional risk factors and
further adjusted for each of the genetic risk scores.
The genetic risk scores used SNPs that were identified
for prevalent rather than incident CHD. To examine
whether this affects their predictive value, we repeated the
analysis separately for prevalent cases. For prevalent CHD,
odds ratios were computed using logistic regression, and
both the predicted risks and NRIs were calculated using
PredictABEL.20 Nagelkerke’s R2 was used to estimate the
variance in incident and prevalent CHD explained by dif-
ferent combinations of risk factors.25
Results
Out of 5899 participants, 485 participants had prevalent
CHD at baseline. During a mean follow-up period of 12.8
years, 964 CHD events (460 myocardial infarctions)
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occurred among the remaining 5414 individuals. Of these
events, 571 (270 myocardial infarctions) occurred within
10 years. Baseline characteristics of the study population
are shown in Table 1, and baseline characteristics by CHD
status are shown in Supplementary Table 2 (available as
Supplementary data at IJE online).
All three genetic risk scores were associated with inci-
dent CHD. The associations were attenuated when adjust-
ing for traditional risk factors, and further attenuated
when additionally adjusted for family history. These asso-
ciations are shown in Table 2. The association between
family history and incident CHD largely remained stable
when the genetic risk scores were added to the model
(Supplementary Table 3, available as Supplementary data
at IJE online).
Improvements in discrimination and reclassification
of incident CHD are shown in Table 3. The largest im-
provement in risk prediction was achieved by GRSall be-
yond age and sex (DC¼ 0.006, 95% CI: 0.000, 0.013);
however, it did not improve reclassification. Furthermore,
improvements in discrimination or reclassification beyond
traditional risk factors or traditional risk factorsþ family
history were very modest. In participants under the age of
65, the genetic risk scores led to greater improvements
in prediction than in the entire sample, although
these were accompanied by larger confidence intervals
(Supplementary Table 4, available as Supplementary data
at IJE online). The associations and improvements in pre-
diction were considerably weaker for incident MI than for
prevalent CHD (Supplementary Tables 5 and 6, available
as Supplementary data at IJE online).
All three genetic risk scores were associated with preva-
lent CHD (Supplementary Table 7, available as
Supplementary data at IJE online), and these associations
were stronger than the associations with incident CHD.
Improvements in the prediction of prevalent CHD were al-
most always markedly higher than improvements in pre-
diction of incident CHD events (Supplementary Table 8,
available as Supplementary data at IJE online). All three
genetic risk scores improved discrimination beyond the
three models. GRSall improved discrimination the most
(DC 0.009 beyond traditional risk factors and family his-
tory, 95% CI: 0.003, 0.015). GRSall also improved reclas-
sification beyond the three models, whereas GRSgws only
improved reclassification beyond ageþ sex and traditional
risk factors. GRSfdr did not improve reclassification be-
yond any of the models.
The percentage of variance in incident and prevalent
CHD explained by the genetic risk scores, risk factors and
their combinations are shown in Supplementary Table 9
(available as Supplementary data at IJE online). Genetic
risk scores consistently explained a larger proportion of
the variance of prevalent CHD than of incident CHD:
GRSall explained 1.5% of the variance of prevalent CHD,
but only 0.7% of the variance of incident CHD. In both
cases, only 0.1% of the variance was also explained by
family history. GRSall explained a larger proportion of the
variance of both incident and prevalent CHD than family
Table 2. Hazard ratios (95% confidence intervals) per SD change of genetic risk scores for incident CHD
Model 1 P-value Bonferroni-
corrected
P-value*
Model 2 P-value Bonferroni-
corrected
P-value*
Model 3 P-value Bonferroni-
corrected
P-value*
GRSgws 1.13 (1.06, 1.20) 0.00014 0.0013 1.12 (1.05, 1.19) 0.00054 0.0049 1.11 (1.05, 1.19) 0.00076 0.0068
GRSfdr 1.09 (1.03, 1.17) 0.0051 0.046 1.08 (1.01, 1.15) 0.02 0.18 1.07 (1.01, 1.14) 0.032 0.29
GRSall 1.15 (1.08, 1.23) 1.1105 9.9105 1.13 (1.06, 1.21) 0.00012 0.0011 1.13 (1.06, 1.20) 0.00022 0.0020
GRSgws, genetic risk score including only CHD SNPs significant according to genome-wide significance; GRSfdr, genetic risk score including only CHD SNPs
significant according to false discovery rate analysis; GRSall, genetic risk score including all significant CHD SNPs.
Model 1: age- and sex-adjusted; Model 2: further adjusted for total and HDL cholesterol, systolic blood pressure, prevalent type 2 diabetes, antihypertensive
medication, lipid-lowering medication and current smoking; Model 3: further adjusted for family history of myocardial infarction.
*Bonferroni-corrected P-values are corrected for nine statistical tests.
Table 1. Baseline characteristics of the 5899 participants
included in this study
Mean (SD) or percentage
Age (years) 69.3 (9.0)
Sex (% males) 40.9
Total cholesterol (mmol/l) 6.6 (1.2)
HDL cholesterol (mmol/l) 1.34 (0.4)
Lipid-lowering medication use 2.5
Antihypertensive medication use 13.3
Systolic blood pressure (mmHg) 139.2 (22.3)
Diastolic blood pressure (mmHg) 73.7 (11.5)
Prevalent type 2 diabetes 10.6
Current smoking 23.1
BMI (kg/m2) 26.3 (3.7)
Parental history of myocardial infarction 37.2
BMI, body mass index.
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history, age, total cholesterol, systolic blood pressure,
smoking and lipid-lowering medication use.
Discussion
In this study we showed that genetic risk scores, based on
up to 152 SNPs so far identified for prevalent CHD, are
associated with incident CHD, though they do not lead to
clinically relevant improvements in 10-year risk prediction
of CHD.
SNPs could be used in CHD risk prediction in two dif-
ferent settings. The first is to use genetic data in adults and
elderly subjects to improve risk prediction beyond current
CHD risk prediction models. Our results show that cur-
rently available SNPs are not sufficient for this application.
A second use of SNPs is to estimate the future risk of CHD
earlier in life. This could be in the form of lifetime risk, or
in the form of 10-year risk at different ages. In this setting,
SNPs are already useful if they improve prediction over age
and sex. Our study suggests that current GWAS findings
may be more useful for this setting.
Several studies have shown that genetic risk scores
based on SNPs for prevalent CHD are associated with inci-
dent CHD, though improvements in prediction are gener-
ally very small.3–7 Ganna et al have previously tested a
genetic risk score similar to GRSgws,
7 and they found
slightly larger improvements in discrimination and reclassi-
fication. In contrast to our study, they recalculated the
weight of each included SNP in an independent prospective
cohort. This step may partly explain the differences be-
tween our studies. Another study suggested that SNPs
might be especially useful in specific subgroups such as
middle-aged men.4 Our study was not sufficiently powered
to examine predictive improvements in this subgroup, but
we did find greater improvements in prediction when we
limited our analysis to participants under 65 years old.
Our genetic risk scores were based on GWA studies.
Given that collecting the large number of cases needed for
adequate statistical power is easier in a case-control setting
with prevalent cases, a large proportion of studies included
in these GWA studies are composed of case-control stud-
ies. Such a design, though statistically more powerful, may
lead to the identification of SNPs that are related to im-
proved survival after events rather than SNPs that increase
the risk of event. This is known as Neyman’s bias or inci-
dence-prevalence bias.26 If so, the identified SNPs for
CHD, and hence the genetic risk score herewith evaluated,
might represent a mixture of SNPs associated with CHD
risk and SNPs associated with an improved survival after a
CHD event. Indeed, we found a striking rise in the incre-
mental value of the genetic risk scores when we used preva-
lent CHD as the outcome instead of incident CHD.
Furthermore, a previous study of prevalent CHD also
found a large C-statistic improvement beyond traditional
risk factors (0.008) in contrast to the small improvements
found by studies of incident CHD.8 This difference sug-
gests that the inability of SNPs to contribute to risk predic-
tion is in part explained by the cross-sectional discovery
panel. This is also supported by our findings, as percentage
of variance explained. For instance, the variance explained
by GRSall in prevalent CHD was twice as large as in inci-
dent CHD. This bias may hamper the ability of genetic risk
scores to improve prediction of first CHD events in popu-
lations free of CHD.27 We present only preliminary evi-
dence that this is influencing risk prediction: prevalent
events occurred earlier in life than incident events, and this
may partly explain the observed differences in risk predic-
tion. Individuals experiencing CHD events at a younger
age may be genetically enriched for CHD SNPs. In line
with this, the percentage of individuals with a family his-
tory of myocardial infarction is slightly higher in prevalent
cases than in incident cases.
A potential solution may be to recalculate the weight of
each included SNP in an independent prospective cohort,
as done by Ganna et al.7 Nevertheless, this approach still
assumes that important SNPs for prevalent CHD are also
important for incident CHD, and did not lead to substan-
tially higher indices of discrimination and reclassification.
Table 3. Improvements in discrimination and reclassification




GRSgws 0.004 (0.001, 0.009) 0.023 (0.021, 0.067)
GRSfdr 0.004 (0.001, 0.008) 0.003 (0.04, 0.046)
GRSall 0.006 (0.000, 0.013) 0.034 (0.014, 0.081)
Model 2 0.716
GRSgws 0.002 (0.001, 0.006) 0.014 (0.019, 0.047)
GRSfdr 0.002 (0.001, 0.005) 0.01 (0.024, 0.044)
GRSall 0.003 (0.001, 0.008) 0.022 (0.018, 0.061)
Model 3 0.716
GRSgws 0.002 (0.001, 0.006) 0.016 (0.019, 0.051)
GRSfdr 0.002 (0.001, 0.004) 0.007 (0.026, 0.04)
GRSall 0.003 (0.001, 0.007) 0.017 (0.025, 0.058)
C, C-statistic before adding genetic risk scores to the model; DC, improve-
ment in C-statistic when adding the genetic risk score to base models; NRI,
net reclassification improvement when adding the genetic risk score to base
models; GRSgws, genetic risk score including only CHD SNPs significant ac-
cording to genome-wide significance; GRSfdr, genetic risk score including only
CHD SNPs significant according to false discovery rate analysis; GRSall, gen-
etic risk score including all significant CHD SNPs.
Model 1 includes age and sex; Model 2 further includes total and HDL
cholesterol, systolic blood pressure, prevalent type 2 diabetes, antihyperten-
sive medication, lipid-lowering medication and current smoking; Model 3 fur-
ther includes family history of myocardial infarction.
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Instead, it may be necessary to conduct a GWAS on inci-
dent CHD restricted to prospective cohort studies.
Conducting large-scale genetic studies in prospective co-
hort studies is likely to lead to more clinically relevant
SNPs for prediction, but there are further developments
that may also achieve this goal. First, increasing the discov-
ery GWAS sample size will continue to lead to more effect-
ive genetic risk scores, by identifying new SNPs and by
refining the effect estimates of known SNPs. Chatterjee
et al. projected that the predictive performance of genetic
risk scores for CHD may keep improving as GWAS sam-
ples increase to as much as 10 times their current size.28
Our study also supports intensifying the discovery effort:
the most effective risk score not only included SNPs ro-
bustly associated with CHD, but also 103 further SNPs
suggestively associated with CHD. Second, denser geno-
typing arrays, denser imputation panels, and exome and
whole-genome sequencing studies may yield low-frequency
and rare variants for CHD that were hidden from GWAS.
Whereas common variants usually have small effect sizes
due to evolutionary constraints, rarer variants may also
have intermediate to large effect sizes. Therefore, although
a single rare variant only explains a small proportion of
variance in the general population, it can explain a large
proportion of variance in families where it is present.
Family history only overlapped slightly with the genetic
risk scores in the variance of CHD explained, providing
largely independent information. Our results suggest that
family history largely tags genetic variants that are not well
covered by GWAS, or aspects of the shared environment
that are independent of traditional risk factors. These hid-
den risk factors appear to affect CHD risk by increasing
the burden of subclinical atherosclerosis.29
This study has certain strengths and limitations. First,
we examined the association between the genetic risk
scores and both incident and prevalent CHD in the same
population, allowing us to compare these associations.
Since associated SNPs were identified using the largest
available GWAS of CHD, a relatively large set of CHD
SNPs with well-estimated weights was used, including mul-
tiple independently associated SNPs per locus when
known. Previous studies have focused on genome-wide sig-
nificant SNPs to include only the most robustly associated
SNPs. This was also our approach for GRSgws, but by
including both genome-wide significant SNPs and suggest-
ively associated SNPs in GRSall, we were able to create a
stronger genetic instrument than GRSgws. In addition, this
study included individuals of 55 years and older, which
corresponds well with the target population for prediction.
On the other hand, our population consisted entirely of
Caucasians, and our results may not be generalizable to
other populations. Furthermore, we used a crude measure
of family history. First, family history was only available
for myocardial infarction and not for CHD in general.
Second, family history was obtained during an interview,
and may not always be complete. Third, participants were
only asked about first-degree relatives. However, these
limitations reflect difficulties in measuring family history
that also arise in clinical practice.
Whereas our results do not support a role for currently
available common SNPs in CHD risk prediction in the
traditional setting, they do suggest that SNPs could already
improve prediction of future CHD earlier in life, when
other variables used in prediction are not yet available.
Our results also suggest that SNPs identified through
GWAS of prevalent disease may not be optimally suited
for the prediction of incident disease. This mismatch may
extend to other diseases with high mortality rates.
Supplementary Data
Supplementary data are available at IJE online.
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